1. |
中国药品综合评价指南项目组. 中国药品综合评价指南参考大纲(第2版). 药品评价, 2015, 12(8): 6.
|
2. |
李洪, 张玉丽, 谢诗桐, 等. 我国医疗保险目录准入申报材料递交的思考与建议-以高血压复方制剂为例. 中国药物经济学, 2018, 13(7): 18-23.
|
3. |
CADTH. Resubmission criteria for the CADTH Common Drug Review. Available at: https://cadth.ca/media/cdr/process/CADTH_CDR_Resubmission_Criteria.pdf.
|
4. |
姚嘉奇, 周挺, 管欣, 等. 英国NICE卫生技术评估介绍及对我国医保目录动态调整的启示. 中国循证医学杂志, 2018, 18(9): 984-989.
|
5. |
NICE. NICE technology appraisal guidance. Available at: https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance.
|
6. |
NICE. Our programmes. Available at: https://www.nice.org.uk/about/what-we-do/our-programmes.
|
7. |
NICE. NICE guidelines. Available at: https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-guidelines.
|
8. |
NICE. Technology appraisal processes. Available at: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/process.
|
9. |
NICE. Guide to the processes of technology appraisal. London: National Institute for Health and Care Excellence, 2014.
|
10. |
NICE. Guide to the methods of technology appraisal 2013. London: National Institute for Health and Care Excellence, 2013.
|
11. |
Gorrod HB, Hernandez M, Grieve R. The use of real world data for the estimation of treatment effects in NICE decision making. London: National Institute for Health and Care Excellence, 2016.
|
12. |
NICE. Developing NICE Guidelines: The Manual. London: National Institute for Health and Care Excellence, 2015.
|
13. |
NICE. Interventional Procedures Programme Manual. London: National Institute for Health and Care Excellence, 2016.
|
14. |
NICE. Diagnostics Assessment Programme Manual. London: National Institute for Health and Care Excellence, 2011.
|
15. |
田磊, 管欣, 马爱霞. 随机对照试验研究与观察性研究的系统比较. 中国药房, 2018, 29(4): 493-496.
|
16. |
李强. 临床疗效研究的金方案:随机对照试验. 世界华人消化杂志, 1999, 7(8): 697-698.
|
17. |
吴宏涛, 周东, 何俐. 非随机对照试验的意义. 中国循证医学杂志, 2004, 4(8): 570-572.
|
18. |
NICE. Single technology appraisal: User guide for company evidence submission template. London: National Institute for Health and Care Excellence, 2015.
|
19. |
Centre for Reviews and Dissemination. CRD's guidance for undertaking reviews in health care. York: York Publishing Services Ltd, 2009.
|
20. |
田磊, 岳彩宾, 管欣, 等. 真实世界研究与随机对照试验在临床实践及卫生决策中应用的比较. 中国医院药学杂志, 2019, 39(3): 274-277.
|
21. |
袁林, 邵明立. 美国FDA加快新药审评策略以及对我国的启示. 中国新药杂志, 2015, 24(21): 2401-2404.
|
22. |
李小芳, 戴伟民, 宋永飞. 对我国药品优先审评审批制度的分析和思考. 中国医药工业杂志, 2019, 50(7): 796-802.
|
23. |
孙鑫, 谭婧, 王雯, 等. 真实世界证据助推药械评价与监管决策. 中国循证医学杂志, 2019, 19(5): 521-526.
|
24. |
FDA. Use of real-world evidence to support regulatory decision-making for medical devices. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices.
|
25. |
符祝, 高国彪, 林尤海. 临床真实世界数据用于药品医疗器械审评审批的探索-海南乐城先行区的实践. 中国食品药品监管, 2019, (6): 4-9.
|